Log in

Ionis Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:IONS)

$58.61
+0.82 (+1.42 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$57.83
Now: $58.61
$58.98
50-Day Range
$53.89
MA: $57.47
$62.91
52-Week Range
$48.27
Now: $58.61
$86.58
Volume620,400 shs
Average Volume1.03 million shs
Market Capitalization$8.24 billion
P/E Ratio19.80
Dividend YieldN/A
Beta1.9
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$599.67 million
Cash Flow$3.25 per share
Book Value$10.65 per share

Profitability

Net Income$273.74 million

Miscellaneous

Employees737
Market Cap$8.24 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.


Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced its quarterly earnings results on Wednesday, November, 6th. The company reported $0.18 earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.49. The business earned $168 million during the quarter, compared to analysts' expectations of $152.47 million. Ionis Pharmaceuticals had a net margin of 52.26% and a return on equity of 36.31%. The business's revenue for the quarter was up 15.9% on a year-over-year basis. During the same period last year, the business earned ($0.03) earnings per share. View Ionis Pharmaceuticals' Earnings History.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Ionis Pharmaceuticals.

What price target have analysts set for IONS?

12 brokers have issued 1-year target prices for Ionis Pharmaceuticals' shares. Their forecasts range from $48.00 to $120.00. On average, they expect Ionis Pharmaceuticals' stock price to reach $74.45 in the next twelve months. This suggests a possible upside of 27.0% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

What is the consensus analysts' recommendation for Ionis Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.

Has Ionis Pharmaceuticals been receiving favorable news coverage?

Headlines about IONS stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ionis Pharmaceuticals earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Ionis Pharmaceuticals.

Are investors shorting Ionis Pharmaceuticals?

Ionis Pharmaceuticals saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 9,110,000 shares, a decrease of 9.2% from the September 30th total of 10,030,000 shares. Based on an average trading volume of 1,020,000 shares, the short-interest ratio is presently 8.9 days. Currently, 7.1% of the shares of the stock are short sold. View Ionis Pharmaceuticals' Current Options Chain.

Who are some of Ionis Pharmaceuticals' key competitors?

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), BlackRock (BLK), Alnylam Pharmaceuticals (ALNY), Alibaba Group (BABA), Biogen (BIIB), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Celgene (CELG) and Allergan (AGN).

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:
  • Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)
  • Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)
  • Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)
  • Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)
  • Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include First Trust Advisors LP (0.70%), Sumitomo Mitsui Trust Holdings Inc. (0.62%), Sicart Associates LLC (0.29%), Tocqueville Asset Management L.P. (0.29%), Nikko Asset Management Americas Inc. (0.26%) and California Public Employees Retirement System (0.21%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Which institutional investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Janney Montgomery Scott LLC, Tocqueville Asset Management L.P., State of New Jersey Common Pension Fund D, Decatur Capital Management Inc., Nisa Investment Advisors LLC, Teacher Retirement System of Texas and Chicago Equity Partners LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Which institutional investors are buying Ionis Pharmaceuticals stock?

IONS stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Prospera Financial Services Inc, Peregrine Capital Management LLC, IFM Investors Pty Ltd, Robeco Institutional Asset Management B.V. and Benjamin F. Edwards & Company Inc.. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $58.61.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $8.24 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.View Additional Information About Ionis Pharmaceuticals.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.


MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  567 (Thanks for Voting!)
Underperform Votes:  638 (Thanks for Voting!)
Total Votes:  1,205
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Featured Article: What are earnings reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel